

Curriculum Vitae

May 23, 2017

Jeff Geohas
May 23, 2017

JEFFREY GEOHAS, MD

Medical Director & Investigator

Evanston Premier Healthcare Research LLC
2500 Ridge Avenue, Suite 109
Evanston, IL 60201
Phone: (847) 869-1191
Fax: (847) 869-6975
Email: jgeohas@evanstonpremier.com

EDUCATION

1985 – 1989 Undergraduate: Northwestern University, Evanston, Illinois, Neurobiology & Physiology
1989 - 1993 Medical: Northwestern University Medical School, Chicago, Illinois

TRAINING

1993 -1994 Internship: Internal Medicine, Evanston Northwestern Healthcare, Evanston, Illinois
Internship: Department of Medicine, Northwestern University, Medical School, Chicago, Illinois
1995 - 1996 Residency: Internal Medicine, Evanston Northwestern Healthcare-Department of Medicine, Northwestern University, Medical School, Evanston, Illinois
1994 Residency: Radiation Oncology, Mallinckrodt Institute of Radiology, Department of Radiation Oncology, Washington University School of Medicine St. Louis, Missouri
1990 Fellowship: Baxter Fellowship

MEDICAL EXPERIENCE

2012 – Present President and Executive Medical Director of Evanston Premier Healthcare Research LLC
2010 – Present Instructor - Clinical Medicine, University of Chicago Pritzker School of Medicine, Evanston, IL
1997 – Present Internist, Private Practice, Evanston, Illinois
2002 – 2010 Medical Director, Radiant Research Chicago Center for Clinical Research, Chicago, IL (Formerly Protocare)
1999 – 2000 Investigator, Chicago Center for Clinical Research, North Shore Satellite, Evanston, IL
1997 – 2010 Clinical Investigator, Radiant Research Chicago Center for Clinical Research, Chicago, IL (Formerly Protocare)
1997 – 2009 Instructor – Clinical Medicine, Northwestern University Feinberg School of Medicine, Evanston, IL

CERTIFICATION AND LICENSURE

Licensure: State of Illinois Physician and Surgeon License Number: 036-093330
2017-present Inform v6.1 for Investigators
2017-present Firecrest ICH GCP (R2)
2016-present IWRS C3.1 v1
2016-present Statin Intolerance IRT Stratification Training v1
2015-present medidata University EDC Essentials for Investigators
2015-present Inform v6 for Investigators
2015-present ClinTrak EDC Training Review
2015-present medidata University Rave EDC Essentials for Investigators
2015-present Synergy Pharmaceuticals ICH GCP
2015-present IV/WRS Site Staff training C3 v2
2015-present Technical Complaint Reporting Inform 4.6 & 6.0

2014-present	SureSource v5 for Investigators
2014-present	epro essentials
2014-present	Medpace ClinTrakEDC training-PI
2014-present	medidata University Rave EDC and Rave Modules
2014-present	Clinical ink SureSource v5 Training
2014-present	AE and SAE Reporting
2014-present	eCRF Completion Guidelines
2014-present	GCP and Study Management
2014-present	Inform GTM 5.5 PI Data Entry and Signature
2013-present	GCP for Investigational Site Staff 2.0
2013-present	eCRF Training for Site Users
2013-present	Clinical Trial Portal – eTMF Training
2012-present	Audits and Inspections v.1
2012-present	Adverse Event Definitions and Reporting in Clinical Studies (Sanofi)
2012-present	Investigator Responsibilities v.1
2012-present	Drug Induced Liver Injury (DILI) v.1
2012-present	Inform v4.6 training
2012-present	CITI Good Clinical Practice Course (GCP)
2012-present	CITI Basic Course
2012-present	CITI Health Information Privacy and Security (HIPS) for all Researchers
2012-present	Biomedical Research, Basic Course
2007-present	Inform v4.5 training

PUBLICATIONS

1. Geohas, J., Roholt, N., Robinson, J. Adjuvant radiotherapy after excision of cutaneous squamous cell carcinoma. *J. Am. Acad. Dermatol* 1994; 30: 663-6.
2. Marymont, M., Geohas, J., Tomita, T., et al. A pilot study of hyperfractional craniospinal radiotherapy in children with medulloblastoma submitted for publication in *J. Ped. Neurosurg*.
3. Singer GM, Geohas, J. The Effect of Chromium Picolinate and Biotin Supplementation on Glycemic Control in Poorly Controlled Patients with Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blinded, Randomized Trial *Diabetes Technol Ther.* 2006 Dec;8(6):636-43
4. Albarracin, C., Fuqua, B., Geohas, J., et al. Combination of Chromium and Biotin Improves Coronary Risk Factors in Hypercholesterolemic Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-Blind Randomized Clinical Trial. *Journal of the CardioMetabolic Syndrome* Volume 2, Issue 2, pages 91–97, Spring 2007
5. Maki, K., Carson, M., Kerr Anderson WH, Geohas, J., Reeves MS, Farmer MV, Turowski M, Miller M, Kaden VN, Dicklin MR, Rains TM. Lipid-altering effects of different formulations of hydroxypropylmethylcellulose . *J Clin Lipidol.* 2009 May-Jun;3(3):159-66. Epub 2009 May 5.
6. Maki, K., Mustad, V., Dicklin, M. and Geohas, J. Postprandial metabolism with 1,3-diacylglycerol oil versus equivalent intakes of long-chain and medium-chain triacylglycerol oils. *Nutrition* 25(6):627-33 (2009) PMID 19217260
7. Smith, S., Church, T., and Geohas, J. Naltrexone SR/Bupropion SR Combination Therapy Reduces Total and Visceral Adiposity in Overweight and Obese Subjects in the COR-I Study. *American Diabetes Association 70th Scientific Meeting (2010).* 70th Scientific Sessions, Abstract 1848-P

AWARDS AND PRIZES

1989 Phi Beta Kappa

RESEARCH ACTIVITIES

- 1994 -1995 Department of Radiation Oncology, Northwestern University Medical School
Chicago, Illinois
- 1994 Department of Dermatology, Northwestern University Medical School
Chicago, Illinois
- 1990 Baxter Fellow, Department of Geriatrics, Northwestern University Medical School, Chicago,
Illinois
- 1989 Department of Biochemistry, Northwestern University, Evanston, Illinois

CLINICAL RESEARCH EXPERIENCE

1. A Multicenter, Randomized, Double-Blind, Four Arm, Parallel Group Trial to Evaluate the Separate and Combined Effects of XXXX and XXXX on Serum Lipids Among Postmenopausal Women with Hypercholesterolemia Co-Investigator: Jeffrey Geohas, MD
2. Multicenter, Double-Blind, Placebo-Controlled, Randomized Study on the Efficacy and Safety of XXXXXX During 3 Years Treatment in Patients with Postmenopausal Osteoporosis and Vertebral Fractures Using A Continuous Oral (2.5 mg daily) and an Intermittent Oral (20 mg every 2nd day for 24 days every 3 months) Dosing Regimen Co-Investigator: Jeffrey Geohas, MD
3. A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Renal Protective Effects of XXXXXX In Patients with Non-Insulin Dependant Diabetes Mellitus and Nephropathy Co-Investigator: Jeffrey Geohas, MD
4. A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of XXXXXX in the Prevention of Bone Loss in Early Postmenopausal Women Co-Investigator: Jeffrey Geohas, MD
5. A 2-Year Open Label, Multicenter, Active XXXXXX Comparison Study, to Evaluate the Effect of XXXXXX on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Co-Investigator: Jeffrey Geohas, MD
6. A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of XXXXXX in the Prevention of Osteoporosis in Postmenopausal Women with Low Bone Mineral Density Co-Investigator: Jeffrey Geohas, MD
7. A Randomized, Double-Blind, Parallel Group Evaluation of XXXXXXXX Compared to XXXXXXXX and XXXXXX/XXXXXXX Once Daily in Patients with Hypercholesterolemia Co-Investigator: Jeffrey Geohas, MD
8. An Investigation of the Pharmacokinetics of XXXXXXXX and the Effects of XXXXXXXX On Semen Characteristics When Administered Daily For 12 Months To Healthy Male Subjects PI: Jeffrey Geohas, MD
9. An Investigation of the Metabolic Rate and Routes of Excretion of XXXXXXXX at Steady State in Healthy Male Subjects PI: Jeffrey Geohas, MD
10. A Multi-Center, Double-Blind, Placebo Controlled Group Comparison Study to Investigate the Efficacy, Tolerance by Patients, and Safety of a Titrated Dose of XXXXXXXX in the Treatment of Hispanic Patients with Non-Insulin Dependent Diabetes Mellitus, Inadequately Controlled by Diet, With or Without XXXXXXXX Treatment PI: Jeffrey Geohas, MD
11. A Twenty-Eight Week, Double-Blind and Observer-Blind to Lipid Values, Active-Controlled, Randomized, Parallel-Group Multi-center Study to Assess the Safety and Efficacy of XXXXXXXX Slow Release Form (80 mg) Administered Once Daily at Bedtime in Patients with Primary Hypercholesterolemia Compared to XXXXXXXX@ 40 mg Co-Investigator: Jeffrey Geohas, MD
12. A Twenty-Eight Week, Open-Label, Multicenter, Extension Study to Prospectively Evaluate the Long-term Safety and Efficacy of XXXXXXXX 80 mg Slow Release (SR) Monotherapy in Patients with Primary Hypercholesterolemia Co-Investigator: Jeffrey Geohas, MD
13. A Comparison of XXXXXXXX and XXXXXX in the Treatment of Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Agents PI: Jeffrey Geohas, MD
14. Safety and Efficacy of Fixed Combination XXXXXXXX/XXXXXXX Products as First Line Therapy In Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control with Diet and Exercise Co-Investigator: Jeffrey Geohas, MD
15. A Double-Blind Randomized Comparison of the Efficacy and Safety of 52 Weeks of XXXXX Therapy Plus Diet in the Treatment of Obesity in Peri- and Post- Menopausal Women at Cardiovascular Risk PI: Jeffrey Geohas, MD
16. A Multicenter, Open-Label, 12 Week Prospective Study to Evaluate the Effectiveness and Tolerability of XXXXXXXX in Hypertensive Patients Participating in the XXXXXXXX Who Have Not Adequately Responded to Angiotensin-Converting Enzyme Inhibitor Monotherapy Co-Investigator: Jeffrey Geohas, MD
17. A Long Term Open Label Extension Trial of a Single Dose of XXXXXXXX in Postmenopausal Women Co-Investigator: Jeffrey Geohas, MD
18. A Long-Term Study of the Safety and Effectiveness of XXXXXXXX Gel for Hormonal Replacement in Hypogonadal Men PI: Jeffrey Geohas, MD

19. Triple-Blind, Randomized, Parallel, Efficacy Study of XXXX vs. XXXXX in Patients with Mild to Moderate Essential Hypertension
PI: Jeffrey Geohas, MD
20. A Multi-Center, Double-Blind, Randomized, Single-Dose, Placebo-Controlled Study to Investigate the Efficacy and Safety of XXXXX and XXXXXX in Preventing Meal-Induced Heartburn Symptoms Following a Provocative Meal PI: Jeffrey Geohas, MD
21. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Factorial Efficacy Trial of Combination Therapy of XXX XXX Plus XXX (Once Daily Dosing) in Adult Patients with Hypertension PI: Jeffrey Geohas, MD
22. A Multicenter, Randomized, Parallel Group Study to Evaluate the Effect of Dosing Time on Efficacy and Safety of XXXX in Patients with Primary Hypercholesterolemia Co-Investigator: Jeffrey Geohas, MD
23. A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Effects of XXXXXX and Continuous Combined Conjugated XXXXXX Plus XXXXXX XXXXXX on Intimal-Medial Thickness of the Carotid Arteries and Bone Mineral Density of the Lumbar Vertebrae and Proximal Femur in Postmenopausal Women PI: Jeffrey Geohas, MD
24. A Phase I Single Center Study in Normal Volunteers for the Purpose of Demonstrating Instrument Setting Procedures on Commercially Available Ultrasound Equipment to be Used with XXXXXX XXXXXX for Injection when Administered Intravenously
PI: Jeffrey Geohas, MD
25. A Multicenter, Randomized, Double-Blind, XXXXXXXX and Placebo Controlled Trial of the Anti-hypertensive Efficacy and Safety of XXXXXX in Black Subjects with Mild to Moderate Hypertension PI: Jeffrey Geohas, MD
26. A 52-Week, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of XXX Treatment in Obese Patients with Type 2 Diabetes Inadequately Controlled with Insulin PI: Jeffrey Geohas, MD
27. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of XXXXXXX XXXXXXX in Patients with Essential Hypertension PI: Jeffrey Geohas, MD
28. Phase IV Post-Marketing Pharmacovigilance of XXXXXXX Treated Plasma PI: Jeffrey Geohas, MD
29. A Single-Dose Cross-Over Study of XXXXX in the Reversal of Broncho-Constriction in Asthmatic Adults PI: Jeffrey Geohas, MD
30. A Multicenter, Six-Week, Randomized, Open-Label, Parallel Arm Study Comparing the Efficacy of XXX XXXXX to XXXXX in Hypercholesterolemic Patients Co-Investigator: Jeffrey Geohas, MD
31. A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of XXXX Administered XXXX in Patients with Type 2 Diabetes who Have Inadequate Glycemic Control with Diet and Exercise PI: Jeffrey Geohas, M. D.
32. A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of XXXXXX Oral Dose Form (Biphasic Tablet) Administered Either Once or Twice a Day in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet And Exercise PI: Jeffrey Geohas, MD
33. Efficacy and Safety of Inhaled Compared with Subcutaneous XXXXXX Therapy in Subjects with Type 2 Diabetes Mellitus: A Six-Month, Outpatient, Parallel Comparative Trial Co-Investigator: Jeffrey Geohas, MD
34. Efficacy and Safety of Inhaled XXXXXX Therapy in Subjects with Type 2 Diabetes Mellitus Not Well Controlled with Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial Co-Investigator: Jeffrey Geohas, MD
35. A Randomized, Placebo-Controlled, Parallel Group (with Subject Option for Treatment Switch), Double-Blind Study (with Open Label Treatment Extension) to Evaluate the Efficacy and Safety of XXXXXXX® (XXXXXX XXXXXX) in Black Americans with Erectile Dysfunction PI: Jeffrey Geohas, MD
36. A 16-Week, Double-Blind and Observer-Blind-to-Lipid-Value, Randomized, Parallel-Group, Multi-center, Active-Controlled Study to Assess the Efficacy and Safety of XXXX Compared to XXXXX Both Administered Every Evening at Bedtime in Patients with Mixed Dyslipidemia
PI: Jeffrey Geohas, MD
37. Phase II Double-Blind, Placebo-Controlled Trial of the Safety, Tolerancation and Efficacy of XXXXXXX and XXXXXX 60 mg/d for the Prevention of Bone Loss in Postmenopausal Women Co-Investigator: Jeffrey Geohas, MD
38. A Comparison of the Effect of Two Doses of XXX with XXXXX ® on Pulmonary Function in Subjects with Mild-To-Moderate Asthma
PI: Jeffrey Geohas, MD
39. XXXXXX vs. XXXXXX Symptoms Relief Study PI: Jeffrey Geohas, MD
40. A Randomized, Double-Blind Controlled Trial Analyzing the Lipid-Altering Effects of XXXXXXX and XXXXXX in Postmenopausal Women
PI: Jeffrey Geohas, MD
41. A Double-Blind, Randomized, Parallel-Group, Multiple-Dose Study to Compare the Efficacy of XXXX/XXXXX Combination, XXXX 10mg, Antacid, and Placebo in Patients With Frequent Heartburn PI: Jeffrey Geohas, MD
42. A Randomized, Placebo-Controlled, Double-Blind, Study to Evaluate the Safety and Efficacy of Subcutaneously Administered XXXXXXX in Obese Subjects Co-Investigator: Jeffrey Geohas, MD

43. A Multicenter, Age-Stratified, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Range Finding Study to Evaluate the Safety and Efficacy of a Fixed Dose Regimen of XXXXXX 2mg and XXXXXX 1mg in Men with Lower Urinary Tract Symptoms PI: Jeffrey Geohas, MD
44. A Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Four Doses of XXXXXX in Obese Patients PI: Jeffrey Geohas, MD
45. A Multicenter, Double-Blind, Randomized, Single-Dose, Placebo-Controlled Study to Investigate the Efficacy and Safety of 20.6 mg and 10.3 mg XXXXX XXXXX in Treating Heartburn Symptoms Following a Provocative Meal Co-Investigator: Jeffrey Geohas, MD
46. A Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of XXXXXXX vs. Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy PI: Jeffrey Geohas, MD
47. An Open-Label, Randomized, Parallel-Group Study to Compare XXXXXXX Plus XXXXXXX vs. XXXXXXX Plus XXXXXXX in the Treatment of Type 2 Diabetes Co-Investigator: Jeffrey Geohas, MD
48. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Clinical Evaluation of Oral XXXXXXX Tablets (2.5mg, 5mg or 7.5mg) as a Monotherapy for 26 Weeks in Subjects with Type 2 Diabetes Mellitus with an Optional 52 Week Open-Label Extension PI: Jeffrey Geohas, MD
49. A Randomized, Double-Blind, Placebo Controlled Trial of XXXXXXX Alone and in Combination with XXXXXXX in Patients with Primary Hypercholesterolemia PI: Jeffrey Geohas, MD
50. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, 6-Week Evaluation of the XXXXXXX 0.4 mg and XXXXXXX 10 mg in Post-Menopausal Women with Hyperlipidemia and a 46-Week Evaluation in which XXXXXXX 0.4 mg and XXXXXXX 0.8mg are Compared to XXXXXXX 201 mg for Long-Term Lipid-Lowering and Bone Mineral Density Effects Co-Investigator: Jeffrey Geohas, MD
51. To Determine the Effect of Increasing Doses of XXXXXXX XXXXXXX Derived XXXXXXX on the Plasma Lipid Levels of Hypercholesterolemic Patients PI: Jeffrey Geohas, MD
52. A Randomized, Double-Blinded Clinical Trial to Evaluate the Influence of XXXXXXX on Serum Lipids in Men and Women with Hypercholesterolemia PI: Jeffrey Geohas, MD
53. Randomized, Double-Blind, Multicenter Phase III Trial of the Comparative Immunogenicity, Safety and Tolerability of Two XXXXXXX PI: Jeffrey Geohas, MD
54. A Double-Blind, Randomized Study of the Safety and Efficacy of a Combination of Insulin and 45 mg of XXXXXXX™ (XXXXXX) Compared to a Combination of Insulin and 30 mg of XXXXXXX™ (XXXXXX) in the Treatment of Patients with Type 2 (Non-Insulin Dependent) Diabetes Mellitus PI: Jeffrey Geohas, MD
55. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Investigate the Efficacy and Safety of Inhaled XXXXXXX 10 mg Administered Twice Daily for Five Days in the Treatment of Symptomatic Influenza A and B Viral Infections in Subjects Aged > 65 Years PI: Jeffrey Geohas, MD
56. A Six Week Trial XXXXXXX XXXXXXX 1 mg Twice Daily as Empirical Therapy in Female Subjects with Symptoms of Diarrhea Predominant Irritable Bowel Syndrome PI: Jeffrey Geohas, MD
57. Long Term Safety of Inhaled XXXXXXX: Extension of Therapy in Subjects with Type 1 or Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials Co-Investigator: Jeffrey Geohas, MD
58. A Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel Group Clinical Trial to Assess the Effect of Three Months Repeated Daily Oral 1200 mg Doses of XXXXXXX in Combination with Oral XXXXXXX, on Glycemic Control and Lipid Profiles in Obese Patients with Type 2 Diabetes PI: Jeffrey Geohas, MD
59. A Phase III Double-Blind Efficacy and Safety Study of XXXXXXX (10 mg) in Addition to XXXXXXX Compared to Placebo in Subjects with Primary Hypercholesterolemia PI: Jeffrey Geohas, MD
60. A Study of Blood Cholesterol Levels in Subjects Consuming a Cholesterol Lowering Diet Including XXXXXXX® PI: Jeffrey Geohas, MD
61. Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Investigate the Safety and Pharmacokinetic Profile of AT-1015 in Patients with Peripheral Arterial Disease Co-Investigator: Jeffrey Geohas, MD
62. Evaluation of XXXXXXX/XXXXXX -Treated Plasma, Isoagglutinin Depleted, In Normal Healthy Volunteers PI: Jeffrey Geohas, MD
63. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of XXXXXXX 12mg/d and Placebo in Females with Constipation-Predominant Irritable Bowel Syndrome (C-IBS) PI: Jeffrey Geohas, MD
64. A Randomized, Double-Blind, Placebo-and Active-Controlled, Parallel Group, Multicenter Study Assessing the Safety and Biological Activity of Oral XXXXXXX XXXXXXX on Biochemical Markers of Bone Remodeling PI: Jeffrey Geohas, MD
65. A Randomized, Single-Dose, Double-Blind, Parallel Study Comparing XXXXXXX 20 mg, XXXXXXX 10 mg and Placebo in Preventing Heartburn When Administered Immediately Prior to a Provocative Breakfast Meal PI: Jeffrey Geohas, MD

66. A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter, Flexible Dose Study to Evaluate the Efficacy and Safety of XXXXXX™ in Males with Erectile Dysfunction and Arterial Hypertension Who Are Taking Multiple Antihypertensive Treatments
PI: Jeffrey Geohas, MD
67. A Phase III Study of the Efficacy and Safety of XXXXXX in Subjects with Symptomatic Benign Prostatic Hyperplasia PI: Jeffrey Geohas, MD
68. A Double-Blind Placebo-Controlled Study of XXXXXX in Patients with Intermittent Claudication due to Peripheral Arterial Disease
PI: Jeffrey Geohas, MD
69. A Randomized, Double-Blind, Placebo Controlled Trial of Once Per Day vs. Split Dosing of XXXXXX XXXXXX in Patients with Hypercholesterolemia Co-Investigator: Jeffrey Geohas, MD
70. A Randomized, Double-Blind Study to Determine the Efficacy of XX in the Treatment of African American Patients with Asthma
PI: Jeffrey Geohas, MD
71. A Double-Blind Comparison of 80 and 160 mg Doses of XXXXXX with Placebo in Hypercholesterolemic Subjects PI: Jeffrey Geohas, MD
72. XXXXXX Cardiovascular Treatment Assessment vs. XXXXXX Co-Investigator: Jeffrey Geohas, MD
73. A 12 Week Double Blind, Placebo-Controlled, Randomized, Multicenter Study to Determine the Efficacy and Safety of XXXXXX in Patients with Low HDL-C and Either Normal or Elevated Triglycerides Co-Investigator: Jeffrey Geohas, MD
74. A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study of XXXXXX for the Treatment of Male Erectile Dysfunction in an At-Home Setting PI: Jeffrey Geohas, MD
75. An Open-Label Continuation Trial of XXXXXX in Male ED Patients Who Previously Participated in XXXXXX PI: Jeffrey Geohas, MD
76. A 16-Week, Double-Blind, Multicenter Study to Evaluate the Effect of XXXXXX in Combination With XXXXXX on Lipids in Patients With Type IIa and IIb Dyslipidemia PI: Jeffrey Geohas, MD
77. A Randomized, Double Blind, Placebo-Controlled and Open-Label Twelve Month Study of the Safety of XXXXXX in Adult Subjects With Insomnia PI: Jeffrey Geohas, MD
78. A Phase III, Vehicle-Controlled Study of Topical XXXXXX Gel Applied 2 Times per Week for 1 Week for Each Recurrence of Herpes Genitalis over 12 Months PI: Jeffrey Geohas, MD
79. A Randomized, Double-Blind, Placebo-Controlled Parallel, Two-Week Efficacy and Safety Study of XXXXXX in Elderly Subjects with Primary Insomnia PI: Jeffrey Geohas, MD
80. A Dose-Ranging Study of XXXXXX In Patients With Primary Hypercholesterolemia PI: Jeffrey Geohas, MD
81. Randomized, Double-Blind, Placebo-Controlled, 14-Day, Dose-Ranging Study of XXXXXX in the Treatment of Subjects with Poor Sleep Quality
PI: Jeffrey Geohas, MD
82. An Open Label, Multi-center, Flexible Dose Escalation Study to Measure Treatment Responsiveness of Quality of Life Instruments in Men with Erectile Dysfunction Treated with XXXXXX PI: Jeffrey Geohas, MD
83. A Double-Blind Placebo-Controlled, Parallel-Group Safety And Efficacy Study Evaluating Three Dose Regimens Of XXXXXX, A Selective Alpha-Adrenergic Antagonist, In The Treatment of Benign Prostatic Hyperplasia PI: Jeffrey Geohas, MD
84. Systolic and Pulse Pressure Hemodynamic Improvement By Restoring Elasticity: The SAPPHIRE Study PI: Jeffrey Geohas, MD
85. Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison of the Efficacy and Safety of Controlled Release XXXXXX and Placebo in the Treatment of Osteoarthritis of the Knee and/or Hip PI: Jeffrey Geohas, MD
86. A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Arm Study to Assess the Long-Term Effects of XXXXXX Versus Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease PI: Jeffrey Geohas, MD
87. Phase III, Vehicle Controlled Study of Topical XXXXXX Gel Applied 2 Times per Week for 3 Weeks for Each Recurrence of Herpes Genitalis over 12 Months PI: Jeffrey Geohas, MD
88. A Randomized, Double-Blind, Multi-Center Study to Assess the Safety of Long-Term Administration of Two Dose Levels of XXXXXX in Patients with Primary Insomnia PI: Jeffrey Geohas, MD
89. XXXXXX in Type 2 Diabetic Subjects: A Fifty-Two Week Double-Blind, Parallel, Active-Controlled Study (Followed by a Fifty-Two Week Open-Labelled Extension) to Investigate Safety and Efficacy PI: Jeffrey Geohas, MD
90. Glycemic Response of Foodstuffs Using a Meal Tolerance Test Sub-Investigator: Jeffrey Geohas, MD
91. A Multicenter, Eight-Week Treatment, Single Step Titration, Open-Label Study Assessing the Percentage of Patients Achieving Low Density Lipoprotein Cholesterol Target With XXXX Starting Doses of XXXXXX PI: Jeffrey Geohas, MD
92. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effects of XXXXXX on Blood Pressure in Men and Women with Mild to Moderate Hypertension PI: Jeffrey Geohas, MD

93. XXXXX in Combination with XXXXX® Versus XXXXX plus XXXXX in Type 2 Diabetes: A Six Month, Double-Blind (with Open-Labelled XXXXX), Multicenter, Randomized, Parallel Study of Efficacy and Safety PI: Jeffrey Geohas, MD
94. XXXXX in Type 2 Hypertriglyceridemic Diabetic Subjects: A Twenty-six Week, Double-Blind, Multicenter, Randomized, Parallel, Active-Controlled (XXXXX plus XXXXX) Study to Investigate Safety and Efficacy PI: Jeffrey Geohas, MD
95. A Randomized, Double-Blind, Multi-Center, Fixed-Dose, Cross-Over Study To Investigate The Efficacy And Safety Of XXXXX Given On Demand In Comparison To XXXXX Given On Demand In Males With Erectile Dysfunction And A Diagnosis Of Diabetes Mellitus And/Or Hypertension And/Or Hyperlipidemia PI: Jeffrey Geohas, MD
96. A Phase I/II Randomized, Double-Blind, Active-Controlled, Dose Escalation Study Of The Safety, Tolerance, Pharmacokinetics, And Antiviral Activity Of XXXXX In Antiretroviral-Naïve Patients Who Are Chronically Infected With HIV-1 PI: Jeffrey Geohas, MD
97. Efficacy and Safety of XXXXX Compared with XXXXX Therapy in Adult Subjects with Type 1 Diabetes Mellitus: A Two-year, Outpatient, Open-label, Parallel-Group Comparative Trial PI: Jeffrey Geohas, MD
98. An Open-Label, Parallel Design, Twelve Month Phase 3 Trial of the Safety and Efficacy of XXXXX in Male Patients with Erectile Dysfunction PI: Jeffrey Geohas, MD
99. A Randomized, Double-Blind, Placebo-Controlled Study Of XXXXX Sustained Release Formulation Prototypes In Subjects With Hypercholesterolemia PI: Jeffrey Geohas, MD
100. A Randomized, Placebo-Controlled Clinical Trial to Evaluate the Effects of XXXXX Consumption on Blood Pressure in Overweight Men and Women with Mild Hypertension PI: Jeffrey Geohas, MD
101. A Multicenter, Randomized, Parallel Group, Double Blind, Placebo Controlled, Flexible Dose Escalation Study to Evaluate Self-Esteem and Overall Relationship in Men with Erectile Dysfunction Treated with XXXXX in the United States PI: Jeffrey Geohas, MD
102. A Randomized, Open Label, Multicenter, Crossover Trial of XXXXX vs XXXXX Utilization on NCEP ATP III Goal Achievement in Persons with Moderate Risk for Coronary Heart Disease: The LAUNCH Study PI: Jeffrey Geohas, MD
103. Efficacy and Safety of XXXXX Compared with Subcutaneous Human Insulin Therapy in Adult Subjects with Type 2 Diabetes Mellitus: A two-year, Outpatient, Open-Label, Parallel Group Comparative Trial PI: Jeffrey Geohas, MD
104. Phase II Dose Ranging Study of XXXXX in Patients with Chronic Pain Due to Osteoarthritis PI: Jeffrey Geohas, MD
105. A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Effects of XXXXX on Blood Pressure in Subjects with Untreated or Sub-optimally Treated Blood Pressure Elevation PI: Jeffrey Geohas, MD
106. A Double-Blind, Randomized, Parallel-Group, Phase III Trial Comparing the Safety and Efficacy of XXXXX and XXXXX and Placebo in Adult Patients with Hypercholesterolemia PI: Jeffrey Geohas, MD
107. An Open-Label, Randomized, Parallel-Group, Multicenter, Phase III Study Comparing the Safety and Efficacy of XXXXX and XXXXX In Adult Patients with Hypercholesterolemia PI: Jeffrey Geohas, MD
108. A Multicenter, Open-Label Extension, Flexible Dose Escalation Study to Evaluate Self-Esteem and Overall Relationships in Men with Erectile Dysfunction Treated with XXXXX in the United States PI: Jeffrey Geohas, MD
109. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, "Factorial" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of XXXXX Combination Tablet in Patients with Primary Hypercholesterolemia PI: Jeffrey Geohas, MD
110. Randomized, Double Blind, Three Way Crossover Comparison of Glucose and Insulin Responses During a Glucose Tolerance Test in Subjects with Type 2 Diabetes Consuming Disease-Specific Versus Standard Nutritional Formulas PI: Jeffrey Geohas, MD
111. Comparison of the Efficacy and Safety of Two Oral Doses of XXXXX or XXXXX, Versus Placebo, as an Aid to Maintenance of Smoking Cessation – A Multiple Country, Randomized, Double-Blind, Five Arm, Placebo-Controlled, Parallel-Group, Fixed Dose, Two-Year, Multi-Center, Phase III Trial; One-Year Treatment, One-Year Follow-Up" PI: Jeffrey Geohas, MD
112. The Efficacy and Safety of the XXXXX Transdermal System for Smoking Cessation PI: Jeffrey Geohas, MD
113. Effects of Induced-Viscosity Formulas on Safety in Healthy Adult Male Subjects PI: Jeffrey Geohas, MD
114. A Prospective, Randomised, Open-Label, Blinded-Endpoint, Parallel Group, Multicentre, Forced-Titration, 14-Week Treatment Study Comparing XXXXX and XXXXX in Patients with Mild-to-Moderate Hypertension using Ambulatory Blood Pressure Monitoring PI: Jeffrey Geohas, MD
115. A Double-Blind, Randomized, Placebo-Controlled, Clinical Study to Evaluate the Effect of XXXXX on Body Fat Mass in Overweight or Obese Men and Women PI: Jeffrey Geohas, MD

116. A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Control, Clinical Evaluation of Insulin Plus XXXXX Compared to Insulin Plus Placebo for 24 Weeks in Subjects with Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin PI: Jeffrey Geohas, MD
117. The Efficacy, Onset of Effect, and Safety of XXXXX Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score (ALF-ACUTE) PI: Jeffrey Geohas, MD
118. An Open-Label Study to Evaluate the Efficacy and Safety of Tadalafil Administered "On Demand" to Men of Various Populations with Erectile Dysfunction PI: Jeffrey Geohas, MD
119. The TROPIC Study: The Dose Response of XXXX/XXXX on Peak Walking Time (PWT) in Patients with Intermittent Claudication-a Matrix Design PI: Jeffrey Geohas, MD
120. A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of XXXX Combination Tablet Versus XXXX in Patients with Hypercholesterolemia PI: Jeffrey Geohas, MD
121. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Safety and Efficacy of XXXX in the Treatment of Rapid Ejaculation PI: Jeffrey Geohas, MD
122. A Double-Blind, Randomized, Parallel-group Pilot Study of Oral XXXX versus placebo in the Prevention of Highly Active Antiretroviral Therapy (HAART)-related Nausea and Vomiting PI: Jeffrey Geohas, MD
123. A Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Effects of a Weight Loss Supplement in Healthy Overweight/Moderately Obese Volunteers PI: Jeffrey Geohas, MD
124. A Twelve Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy of XXXX of Comparison to XXXX[®] For Smoking Cessation PI: Jeffrey Geohas, MD
125. A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Study to Evaluate the Improvement in Glycemic Control After Daily Administration of Chromium Picolinate and Biotin in Patients With Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
126. A 12-Month, Open-Label, Flexible-Dosage (xxx to xxx mg/day) Study of the Safety and Efficacy of XXXX in the Treatment of Patients With Excessive Sleepiness Associated With Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder. PI: Jeffrey Geohas, MD
127. A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 3 Bridging Trial of the Efficacy and Safety of XXXXX in Male Subjects with Erectile Dysfunction PI: Jeffrey Geohas, MD
128. An Open-Label, Long-Term, Phase 3 Trial of the Safety and Efficacy of XXXXX in Male Subjects with Erectile Dysfunction PI: Jeffrey Geohas, MD
129. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Phase III Study to Assess the Efficacy and Safety of XXXX, With and Without Food, Versus a Matching Placebo, Combined With a Low Saturated-Fat Diet in Subjects with Hypertriglyceridemia and Metabolic Syndrome PI: Jeffrey Geohas, MD
130. A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Multicenter Study to Evaluate the Improvement in Glycemic Control, Lipid Levels, Quality of Life and Healthcare Costs After Daily Administration of XXXX in Patients With Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
131. A Phase I/II Study to Evaluate the Safety, Tolerance and Immunogenicity of XXXX Influenza Vaccine versus XXXX Influenza Vaccine in Healthy Adults 50-64 Years of Age and Elderly Adults ≥ 65 Years of Age PI: Jeffrey Geohas, MD
132. A 24-Week, Randomized, Double-Blind, Multi-Centre, Active-Controlled (XXXX) Study to Evaluate the Efficacy, Safety and Tolerability of XXXX Therapy when Administered to Patients with Type 2 Diabetes PI: Jeffrey Geohas, MD
133. A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient Study to Assess the Efficacy and Safety of an Immediate Release Formulation of XXXX in Elderly Primary Insomnia Patients with Sleep Maintenance Difficulties PI: Jeffrey Geohas, MD
134. A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Efficacy and Safety Extension Study of XXXX in the Treatment of Adult Outpatients With Primary Insomnia PI: Jeffrey Geohas, MD
135. A Clinical Study to Identify Normal Healthy Adults Without *in vitro* Serum Bactericidal Activity (SBA) Against *N. meningitidis* and to Obtain Blood Donations From Selected SBA Negative Donors PI: Jeffrey Geohas, MD
136. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment with XXXX in Adult Subjects with Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data PI: Jeffrey Geohas, MD
137. A Double-Blind, Multi-center, Active-Controlled (XXXX) Long-Term Extension Study to Evaluate the Safety and Tolerability of XXXX in Patients with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
138. Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of XXXX Vs. XXXX as Vaccines for Japanese Encephalitis in Healthy Volunteers PI: Jeffrey Geohas, MD

139. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing With XXXX in the Treatment of Premature Ejaculation PI: Jeffrey Geohas, MD
140. A Phase 2B, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Examine the Effect of Pramlintide on Body Weight and It's Safety and Tolerability in Obese Subjects PI: Jeffrey Geohas, MD
141. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined XXXX and Simvastatin Therapy in Hypertriglyceridemic Subjects PI: Jeffrey Geohas, MD
142. An Open-Label Pilot Study to Assess the Safety and Immune Effects of Dietar Supplementation with DIAM-H-04-2 PI: Jeffrey Geohas, MD
143. A Pilot Clinical Trial to Assess the Safety and Tolerability of XXXX in Healthy Adults PI: Jeffrey Geohas, MD
144. A 12-Week, Dose-ranging, Double-blind, Randomized, Placebo-controlled, Parallel group Study to Assess the Safty and Efficacy of XXXX in Obese Patients Principle Investigator: Jeffrey Geohas, MD
145. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of XXXX Influenza Vaccine in Healthy Adults 18 – 49 Years of Age PI: Jeffrey Geohas, MD
146. A Randomized, Double-Blind, Controlled, Parallel Study to Test the Efficacy of XXXX for Enhancing Loss of Fat Mass in Overweight and Obese Men and Women Undergoing a Mild Energy Restriction PI: Jeffrey Geohas, MD
147. A Multicenter, Placebo Controlled, Randomized, Double-Blind, Subject Initiated Study of the Safety and Efficacy of a Single Topical XXXX Application of XXXX Cream with an Open Label Conventional Therapy Treatment Arm, and a Blinded Evaluator, for the Episodic Treatment of Recurrent Herpes Labialis PI: Jeffrey Geohas, MD
148. Extension Study of Protocol 137OB-201E to Examine the Long-Term Effect of XXXX on Body Weight and It's Safety and Tolerability in Obese Subject PI: Jeffrey Geohas, MD
149. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Effects on Lipids of 12 Weeks of 2 Doses of XXXX in Subjects With Primary Hypercholesterolemia PI: Jeffrey Geohas, MD
150. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX PI: Jeffrey Geohas, MD
151. A Non-Inferiority Comparison of XXXX Influenza Virus Vaccine to a US Licensed Inactivated Split-Virion Vaccine (XXXX) in Adults ≥ 50 Years Old Living in the Community PI: Jeffrey Geohas, MD
152. A Multicenter, Randomized, Double Blind, Phase III Study of the Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (XXXX and XXXX) PI: Jeffrey Geohas, MD
153. A Long-Term, Post Treatment, Safety Follow-up, Multi-Centre Study in Patients with Type 2 Diabetes Mellitus from the GALLANT, GALLFX or ARMOR Studies PI: Jeffrey Geohas, MD
154. A 6-week, multicenter, randomized, double – blind, parallel – group treatment regimen study to evaluate the efficacy of initial high dose XXXX monotherapy (160mg) or combination therapy (XXXX + XXXX, 160/12.5mg) to conventional low – dose XXXX monotherapy (80mg) in managing patients with hypertension PI: Jeffrey Geohas, MD
155. An Open – Label Extension of a Randomized, Double – Blind, Placebo – Controlled Study to Assess the Efficacy and Safety of Combined XXXX and XXXX Therapy in Hypertriglyceridemic Subjects PI: Jeffrey Geohas, MD
156. An Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX PI: Jeffrey Geohas, MD
157. Observer Blinded, Randomized Phase 3 Study to Investigate the Non-Inferiority of XXXX (XXXX) vs. XXXX as Vaccines for Japanese Encephalitis in Healthy Subjects PI: Jeffrey Geohas, MD
158. Phase I/II, Double-Blind, Randomized Study to Assess the Safety and Immunogenicity of XXXX Supplied by Two Different Manufacturers in Healthy Adults PI: Jeffrey Geohas, MD
159. An Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX PI: Jeffrey Geohas, MD
160. A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive XXXX Therapy in Hypertriglyceridemic Subjects Treated with XXXX PI: Jeffrey Geohas, MD
161. A Phase II Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Epidemiology of Natural Infection with Enterotoxigenic Escherichia coli Occurring after Transcutaneous Immunization in a Field Setting PI: Jeffrey Geohas, MD
162. A 104-Week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety and Efficacy of XXXXXXX in Obese Patients PI: Jeffrey Geohas, MD
163. Immunogenicity and Safety of The Split, Inactivated, Trivalent XXXXXXXX Administered by Intradermal Route in Comparison with XXXXXXX with Standard XXXX in Ambulatory Elderly Subjects PI: Jeffrey Geohas, MD

164. A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of XXXX Influenza Vaccine in Healthy Adults 18-49 Years of Age (Season #2) PI: Jeffrey Geohas, MD
165. A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of XXXXX on Body Weight in Obese Subjects. PI: Jeffrey Geohas, MD
166. A Phase 2A, Randomized, Controlled, Double-Blind, Multicenter Study To Evaluate The Safety, Tolerability, and Effect On Body Weight of XXXXXX Human Leptin Administered In Conjunction with XXXXXX In Overweight And Obese PI: Jeffrey Geohas, MD
167. A randomized, double-blind, active-controlled, vehicle-controlled, subject initiated study comparing efficacy and safety of XXXXXX versus XXXXXX for treatment of recurrent herpes simplex labialis PI: Jeffrey Geohas, MD
168. A Multi-Center, Double-Blind, Parallel-Group, Randomized Study Comparing the Efficacy and Safety of XXXXXX versus XXXXXX as Add-On Therapy in Subjects with Type 2 Diabetes Mellitus Inadequately Controlled on the Maximum Effective Dose of XXXXXXXX and Combination Therapy PI: Jeffrey Geohas, MD
169. Multicenter, Randomized, Double-Blind Titration Study to Evaluate and Compare the Efficacy and Safety of XXXX Added On to XXXXX versus Up Titration to XXXXXX in Hypercholesterolemic Patients at Moderately High Risk for Coronary Heart Disease Not Adequately Controlled on XXXXX PI: Jeffrey Geohas, MD
170. Multicenter, Randomized, Double-Blind Titration Study to Evaluate and Compare the Efficacy and Safety of XXXX Added On to XXXXX versus Up Titration to XXXX in Hypercholesterolemic Patients at High Risk of Coronary Heart Disease No Adequately Controlled on XXXX PI: Jeffrey Geohas, MD
171. A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of XXXXX on Symptomatic Peripheral Arterial Disease PI: Jeffrey Geohas, MD
172. A Phase III Clinical Trial to Evaluate the Safety and Tolerability of XXXXX in Subjects 50 to 59 Years of Age PI: Jeffrey Geohas, MD
173. A Study Evaluating the Co-Administration of XXXXXX in combination with Aspirin to Minimize Flush with Placebo Control and Double Blinding PI: Jeffrey Geohas, MD
174. Safety and Immunogenicity of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed XXXXXX in person \geq 65 Years of Age PI: Jeffrey Geohas, MD
175. Phase I/II Randomized Study to Evaluate the Safety and Immunogenicity of Transcutaneous Trivalent XXXXXXXXXXXX with Different Doses of Heat-Labile Enterotoxin of Escherichia coli in Healthy Adults PI: Jeffrey Geohas, MD
176. A Phase II, 28-day Partially Blinded, Multicenter, Randomized, Parallel-group Study to Evaluate 200 and 300 ug Daily XXXXXXXXXXXX compared to Daily Forteo on Bone Turnover Makers, Pharmacokinetics, and Safety in Postmenopausal Women PI: Jeffrey Geohas, MD
177. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of The Combination of XXXXXX And XXXXXX 20 MG VS XXXXXX In Subjects with Moderate Hypercholesterolemia PI: Jeffrey Geohas, MD
178. A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of the Electrokinetic Transdermal System with XXXXXXXXXXXX for the Episodic Treatment of Recurrent Herpes Labialis P: Jeffrey Geohas, MD
179. A prospective, multi-center, paired data, cohort screening trial comparing XXXXX to the Fasting Plasma Glucose Test in Subjects at Risk for Diabetes PI: Jeffrey Geohas, MD
180. A Randomized, Double-Blind, Crossover Study to Compare the Effects of XXXXX and XXXXX on Postprandial Glucose in subjects with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
181. A Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Type 2 Diabetes Mellitus Who Have a Haptoglobin Type 2-2 Genotype and a History of Coronary Artery Disease PI: Jeffrey Geohas, MD
182. A Phase 3, 53 Weeks Study on Analgesic Efficacy and Safety of XXXXXX: 26-week, Randomized, Parallel-Group, Double-Blind, Placebo (13 Weeks) – and XXXX (26 Weeks)- Controlled, Multicenter Study XXXXXX (375 mg bid and 750 mg bid) with a 26-Week XXXXX-Controlled Safety Follow-up in Subjects with Osteoarthritis of the Knee, and a 1-Week Post-treatment Safety Follow-up PI: Jeffrey Geohas, MD
183. A Phase IV Clinical Trials to Evaluate the Safety and Tolerability of XXXXXX in Subjects \geq 60 Years of Age PI: Jeffrey Geohas, MD
184. A Phase 2 12 Week, Multi-Center, Randomized Double-Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study Evaluating the Efficacy, Tolerability and Safety of XXXXXXXXXXXX Succinate For Stress Urinary Incontinence in Women PI: Jeffrey Geohas, MD
185. A Phase 2, 12 Week, Multi-Center, Randomized Double Blind, Placebo Controlled, Parallel Group, Dose Range Finding Study Evaluating The Efficacy, Safety and Tolerability of XXXXXXXXXXXX Succinate For Urge Urinary Incontinence in Women PI: Jeffrey Geohas, MD
186. A Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0, 800 or 1600 mg/day of XXXXXX Administered Orally Once Daily with a Reduced Caloric Diet in Obese Males and Females PI: Jeffrey Geohas, MD
187. A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of XXXXXXXXXXX in Adult Subjects with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD

188. A Phase III Randomized, Evaluator-Blind, Parallel Group Study of the Safety and Efficacy of XXXXXXXXX Capsules and Placebo in the Treatment of Onychomycosis of the Toenail PI: Jeffrey Geohas, MD
189. A Randomized, Double-Blind, Multiple-Site, Placebo-controlled Study comparing XXXXXX to XXXXXX in the Treatment of Acne Vulgaris PI: Jeffrey Geohas, MD
190. A Multi-Center, Randomized, Double-Blind, "Crossover" Design Study to Evaluate the Lipid-Altering Efficacy and Safety of XXX Combination Tablet compared to XXXXXX +XXXXXX in Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia PI: Jeffrey Geohas, MD
191. Efficacy And Safety Of XXXXXXXX In The Treatment of Hypogonadal Men With Erectile Dysfunction Unresponsive To PDE5 Inhibitors: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Study PI: Jeffrey Geohas, MD
192. A 12-Week, Multi-Center, Double-Blind, Randomized, Parallel-Group Study, Followed by a 12 Month Extension Study, of the Efficacy and Safety of LCP-Atorfen in Subjects with Dyslipidemia PI: Jeffrey Geohas, MD
193. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of A XXXXXXXXX Flexible Dose Regimen in Patients With Overactive Bladder PI: Jeffrey Geohas, MD
194. Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and lot Consistency of XXXXXXXX Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 PI: Jeffrey Geohas, MD
195. Immunogenicity and Safety of two dosages of the split, inactivated, trivalent XXXXXX XXXXXX administered by Intradermal Route in the Elderly Compared with Standard XXXXXX in Adults and Elderly Subjects PI: Jeffrey Geohas, MD
196. A Prospective, multi-center, paired data, cohort screening trial comparing XXXXXXXX to the Fasting Plasma Glucose Test in Subjects at risk for diabetes PI: Jeffrey Geohas, MD
197. A Double Blind, Multi-Center, Randomized, Parallel-Group, Yearlong Study to Assess the Efficacy and Safety of 0 or 1600 mg/day of XXXXXXXX Administered Orally Once Daily with an Initial 6-Week low Caloric Diet in Obese Males and Females PI: Jeffrey Geohas, MD
198. Immunogenicity of two Dosages of a Split, Cell-Based, Inactivated, Trivalent XXXXXXXX Produced in the PER.C6 Line, Administered in Healthy Adult Subjects Aged 18 to 49 Years PI: Jeffrey Geohas, MD
199. Phase 3 Double Blind Clinical Study Comparing The Effectiveness and Safety of XXXXXXXXX With XXXXXXXX In The Prevention Of XXXXXXXX like Illness PI: Jeffrey Geohas, MD
200. Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational XXXXXXXX to Prevent Culture Confirmed XXXXX PI: Jeffrey Geohas, MD
201. Double-Blind, Parallel-Group Comparison of 23 mg XXXXXXXX Sustained Release to 10 mg XXXXXXXX Immediate Release in Patients with Moderate to Severe Alzheimer's Disease PI: Jeffrey Geohas, MD
202. A Double-blind, Randomized, Controlled Trial to Assess the Influence of Consuming XXXXXXXX on Fasting Lipids in Men and Women with Primary Hypercholesterolemia PI: Jeffrey Geohas, MD
203. A 54-week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of XXXXXX as adjunctive therapy to acetylcholinesterase inhibitors on cognition and overall clinical response in XXXX subjects with mild to moderate Alzheimer's disease PI: Jeffrey Geohas, MD
204. A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Effects Of XXXX on Cognitive Functions In The Elderly PI: Jeffrey Geohas, MD
205. A Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity, Safety and Tolerability of XXXXXX in Subjects 50 to 59 Years of Age PI: Jeffrey Geohas, MD
206. Open Label Study of the Effect of Daily Treatment with XXXXXX in Subjects with Dementia of the Alzheimer's Type PI: Jeffrey Geohas, MD
207. Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXXXXXXX on Measures of Cognition, Activities of Daily Living, and Global Function in Subjects with Mild Dementia of the Alzheimer's Type PI: Jeffrey Geohas, MD
208. Phase 3 Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with XXXXX on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type PI: Jeffrey Geohas, MD
209. A Prospective, 5-Week, Open-Label, Randomized, Multi-Center, Parallel-Group Study with a 20-Week, Open-Label Extension Evaluating the Tolerability and Safety of Switching from XXXXX to an initial dose of XXXXXXXX Formulation in Patients with Probable Alzheimer's Disease PI: Jeffrey Geohas, MD
210. A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of XXXXXX Sustained Release XXXXXXXX Sustained Release and Placebo in Obese Subjects PI: Jeffrey Geohas, MD
211. A Multi-Site, Cross-Sectional, Non-Treatment, Prospective Trial to Collect XXXXXX and XXXXXXXX data from cognitively normal elderly subjects PI: Jeffrey Geohas, MD

212. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Dose Response of XXXXXXXX Compared to Open-Label Atrovastatin in Patients with Hypercholesterolemia PI: Jeffrey Geohas, MD
213. "A randomized, multicenter, double-blind, placebo-controlled, 18-month study of the efficacy of XXXX in patients with mild-to-moderate dementia of the Alzheimer's type" PI: Jeffrey Geohas, MD
214. A Phase III Randomized, Double-Blind, Placebo Controlled Multicenter study to Determine the Safety and Efficacy of XXXXX ion the Treatment of Obesity in Adults with Obesity-Related Co-Morbid Conditions PI: Jeffrey Geohas, MD
215. A Long-Term Safety and Efficacy Study of XXXXXXXX in Elderly Subjects With Primary Chronic Insomnia PI: Jeffrey Geohas, MD
216. Assessment of the Content Validity of the Flushing ASsessment Tool (FAST) PI: Jeffrey Geohas, MD
217. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination of XXXXXXXX (Formerly BMS 201038) and XXXXX 20mg vs XXXXXXXX in Subjects with Moderate I Hypercholesterolemia PI: Jeffrey Geohas, MD
218. A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of XXXXXXXX 50mg or Placebo When Coadministered With Statins in Subjects With Hypercholesterolemia, With an Optional Open-Label Extension PI: Jeffrey Geohas, MD
219. A 52-Week, Double-blind, Randomized, Placebo-controlled, Parallel-Group Study to Assess the Safety and Efficacy of XXXXX in Overweight and obese Patients PI: Jeffrey Geohas, MD
220. A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multi-Center Study with a Double Blind Extension Investigating the Efficacy and Safety of a Fast-Dissolving XXXXX Formulation of XXXXXXXX for ther Treatment of Nocturia in Adults PI: Jeffrey Geohas, MD
221. A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fast-Dissolving XXXXXXXX Formulation of XXXXXXXX for the Treatment of Nocturia in Adults PI: Jeffrey Geohas, MD
222. A phase IIb, multi-center, randomized, double-blind, placebo-controlled study, with open-label follow on, to evaluate the efficacy, safety and tolerability of XXXXX in Subjects with Premature Ejaculation (PE) PI: Jeffrey Geohas, MD
223. A Randomized, Double Blind, Placebo-Controlled, Parallel Group Safety to Demonstrate the Subjective Treatment Effects of XXXXXXXX on Sleep Using a Post Sleep Questionnaire-Interactive Voice Response System in an "At-Home Setting" in an Adult Population with Chronic Insomnia PI: Jeffrey Geohas, MD
224. A 12-Month, Open-Label, Extension Study of the Safety and Efficacy of XXXXX in Subjects with Dyslipidemia PI: Jeffrey Geohas, MD
225. A 12-Week, Phase 2A, Randomized, Subject and Investigator Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of XXXXXXXX on Glucose Control and Body Weight in Overweight Adult Subjects with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
226. Evaluation of XXXXXXXXXXXX on Carotid Intima-Media Thickness in Subjects with Type IIa and IIb Dyslipidemia with Residual Risk in Addition to Atorvastatin Therapy (FIRST) Trial PI: Jeffrey Geohas, MD
227. A Phase 3, Observer-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and immunogenicity of a two-dose series of XXXXXXXX XXXXXXXX antigen in association with XXXXX adjuvant in adults aged ≥ 18 years PI: Jeffrey Geohas, MD
228. Open-Label Extension Study of 23 mg XXXXXXXX in Patients with Moderate to Severe Alzheimer's Disease PI: Jeffrey Geohas, MD
229. A Prospective, multi-center, paired data, cohort screening trial comparing XXXXXXXX to the Fasting Plasma Glucose Test in Subjects at risk for diabetes PI: Jeffrey Geohas, MD
230. A Phase 2, 240Week, Multicenter, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate The Effect of XXXXX on Bone Mineral Density In Postmenopausal Women With Low Bone Mineral Density PI: Jeffrey Geohas, MD
231. 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate The Efficacy and Safety Of XXXXXXXX In Comparision To Tolterodine ER in Patients With overactive Bladder PI: Jeffrey Geohas, MD
232. A Post Hoc Study to Evaluate the Baseline Surrogate Biomarkers of Oxidative Stress and Inflammation in Subjects with Type 2 Diabetes Mellitus Who Have a Haptoglobin Type 1-1 Genotype and a History of Coronary Artery Disease PI: Jeffrey Geohas, MD
233. A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of XXXXX Administered in Conjunction with XXXX in Obese and Overweight Subjects PI: Jeffrey Geohas, MD
234. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) XXXXXXXX When Added to Ongoing Lipid-Modifying Therapy in Dyslipidemic Patients PI: Jeffrey Geohas, MD
235. A Randomized, Open-Label, Parallel-Group, Multicenter Study to Evaluate the Comparability of the Glycemic Effects of XXXXXXXX once weekly from two different manufacturing sites in subjects with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
236. 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of XXXXXXXX in Comparison to Tolterodine ER in Patients with Overactive Bladder PI: Jeffrey Geohas, MD
237. A Phase IIb, Multi-Center, Dose-Parallel, Randomized, Double-Blind, Monotherapy and Placebo-Controlled Safety and Efficacy Study of XXXXXXXX plus XXXXXXXX Combination Therapy in Subjects with Uncomplicated Obesity PI: Jeffrey Geohas, MD

238. A Phase I, Randomized, Observer-blind, Multicenter, Dose Ranging Study to Evaluate the Immunogenicity, Safety and Tolerability of Different Formulations of an Adjuvanted or Non-Adjuvanted XXXX Submit Influenza Virus Vaccine in Healthy Subjects 18 – 40 Years of Age
PI: Jeffrey Geohas, MD
239. A Phase 2, Observer-blind, Randomized, Multi-Center Trial to Evaluate the Safety and Immunogenicity of Heterologous Booster Vaccination with XXXXXXXXXXXX Vaccine Adjuvanted with XXXX given 6 or 12 Months following a single priming dose of XXXXXXXXXXXX Vaccine Antigen Adjuvanted with AS03 in Adults 18 years of age or older PI: Jeffrey Geohas, MD
240. Open-Label Extension (OLE) Safety and Efficacy Study of XXXXXX following The Year-Long Controlled Clinical Trials of XXXXXX in Obese Males and Females PI: Jeffrey Geohas, MD
241. Lot Consistency, Immunogenicity, and Safety Study of Three Lots of XXXXXX Vaccine Administered by Intradermal Route in Comparison with Standard XXXXXXXX® Administered Intramuscularly in Adult Subjects Aged 18 to 64 Years PI: Jeffrey Geohas, MD
242. Safety and Immunogenicity of Revaccination with XXXXXX in Ambulatory Elderly Subjects Previously Vaccinated with XXXX IM
PI: Jeffrey Geohas, MD
243. Extension Study of Protocol DFA102 To Examine The Long-Term Safety, Tolerability, And Effect On Body Weight Of XXXXXX Administered in Combination with XXXXXXXX in Obese And Overweight Subjects PI: Jeffrey Geohas, MD
244. Phase 3 Double Blind Clinical Study of Effectiveness and Safety of Vero Cell-Derived, Trivalent, Seasonal XXXXXX in Adults 50 Years of Age and Older PI: Jeffrey Geohas,
245. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Examine the Safety, Tolerability, and Effect on Body Weight of Subcutaneous AC2307 in Obese or overweight subjects PI: Jeffrey Geohas, MD
246. Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived XXXXXXXX to Prevent Culture Confirmed XXXXXXXX Infection PI: Jeffrey Geohas, MD
247. A multicenter, double-blind, randomized, 12-month, placebo-controlled study to evaluate the lipid-lowering effect, safety and tolerability of XXXXXXXXXXXX 25 mg/day and 50mg/day when added to ongoing stable statin therapy (HMG-CoA reductase inhibitors) in patients with primary hypercholesterolemia PI: Jeffrey Geohas, MD
248. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Different Doses of XXXXXX in Combination With a Statin vs. Statin Mono-Therapy in Patients With Hyperlipidemia PI: Jeffrey Geohas, MD
249. A Phase II, Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel Group Study Evaluating the Efficacy, Safety and Tolerability of XXXXXXXX Administered Twice Daily for 24 Weeks in Treatment-naïve, Metformin Only or Metformin plus Sulfonylurea-treated Obese Type 2 Diabetic Patients (PROMOTIE) PI: Jeffrey Geohas, MD
250. Safety and Immunogenicity of Revaccination with Influenza Vaccine in Healthy Adult Subjects aged 18 to 64 Years who were Previously Vaccinated with XXXXXXXX or XXXXXXXX PI: Jeffrey Geohas, MD
251. A study to evaluate the safety, immunogenicity, and relative efficacy of A/California/7/2009 (H1N1)v-like vaccines GSK2340274A and GSK2340273 in adults aged 18 years and older PI: Jeffrey Geohas, MD
252. An Observer-Blinded, Randomized, Parallel-Group, Multi-Center Study Comparing the Safety and Immunogenicity of XXXXXXXXXXXX to Licensed Vaccine (Engerix-B) among Healthy Subjects 40 to 70 Years of Age PI: Jeffrey Geohas, MD
253. A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXX in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with their Lipid Modifying Therapy PI: Jeffrey Geohas, MD
254. A Phase 2, Randomized, Double-blind, Double-dummy, Placebo and Active-controlled, Multicenter, Parallel Group Study to Evaluate the Efficacy and Safety of XXXX in Patients with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
255. PDT-01-Safety and Efficacy of XXXX in Patients with Hyperlipidemias: A Pilot Study PI: Jeffrey Geohas, MD
256. Phase 2, Double-Blind, Placebo Controlled, Randomized Withdrawal, Parallel Efficacy and Safety Study of XXXXXXXX in Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder
Co-Investigator: Jeffrey Geohas, MD
257. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Assess the Effects of XXXXXXXX on Women with Recent History of Urinary Tract Infections PI: Jeffrey Geohas, MD
258. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXXXXX in Patients with Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy PI: Jeffrey Geohas, MD
259. A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and tolerability of XXX once Weekly Suspension to XXXXX and Placebo in Subjects with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
260. A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the efficacy and safety of XXXXXX to that of XXXX XXXX once daily and XXXX three times daily in patients with Type 2 diabetes insufficiently controlled with XXX XXXX with or without metformin
PI: Jeffrey Geohas, MD

261. An Efficacy and Safety Study of XXXX in Adults with Hypertriglyceridemia PI: Jeffrey Geohas, MD
262. A Double-blind, Randomized, Placebo-controlled, Phase 3 Trial in Patients with Chronic Idiopathic Constipation to Demonstrate the Efficacy and Safety of XXXXX for 12 Weeks Followed by a 4-week Withdrawal Period PI: Jeffrey Geohas, MD
263. A Multicenter, Open-label, Safety and Tolerability Extension Trial of XXXXX Daily in the Treatment of Chronic Idiopathic Constipation PI: Jeffrey Geohas, MD
264. A Randomized, Double-Blind, (Test Products and Placebo), Chronic Dosing (24 Weeks), Placebo-Controlled, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of XXXX, XXXX, and XXXX in Subjects With Moderate to Very Severe COPD, Compared With Placebo and XXXX (XXXX, Open-Label) as an Active Control PI: Jeffrey Geohas, MD
265. A 28-Week, Multi-Center, Randomized, Double-Blind, Parallel-Group, Active-Controlled Safety Extension Study to Evaluate the Safety and Efficacy of XXXX, XXXX, and XXXX in Subjects With Moderate to Very Severe COPD, With XXXXX as an Active Control PI: Jeffrey Geohas, MD
266. A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral XXXXX Compared With XXXXXX When Used in Combination With Metformin in Subjects With Type 2 Diabetes PI: Jeffrey Geohas, MD
267. A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12-Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of XXXXX mg Once Daily Versus Placebo in Statin-Naïve or Statin-Stable Hypertriglyceridemic Subjects PI: Jeffrey Geohas, MD
268. A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of XXXX Peptide Immunotherapy in Cat Allergic Subjects Co-Investigator: Jeffrey Geohas, MD
269. A Multicenter, Randomized, Double-Blind, Placebo-Controlled 12 Week Phase II Proof of Concept Study to Evaluate the Efficacy and Safety of XXXXXX Once Daily Versus Placebo in Statin Stable Subjects with Mixed Dyslipidemia PI: Jeffrey Geohas, MD
270. A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men with Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment with XXXX or XXXX PI: Jeffrey Geohas, MD
271. A 20-week, double-blind, randomized, placebo-controlled, parallel-group trial to assess the safety and efficacy of XXXX on body weight in obese subjects without diabetes PI: Jeffrey Geohas, MD
272. A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study To Assess The Efficacy, Safety And Tolerability Of XXXXX In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events PI: Jeffrey Geohas, MD
273. Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, and Tolerability Of XXXXX, In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects PI: Jeffrey Geohas, MD
274. Phase 3 Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of XXXXX, In Reducing The Occurrence Of Major Cardiovascular Events In Subjects At High And Very High Risk PI: Jeffrey Geohas, MD
275. A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of XXXXXX twice daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
276. A Phase II, 16-week, double-blind, placebo-controlled, parallel-group, randomized, multicentre trial to assess effect on glycaemic control of three doses of XXXXX in subjects with inadequately controlled type 2 diabetes receiving a stable dose of metformin PI: Jeffrey Geohas, MD
277. Open-Label Extension Study of EFC12492, R727-CL-1112, EFC12732, & LTX11717 Studies to Assess the Long-Term Safety and Efficacy of XXXXX in Patients with Heterozygous Familial Hypercholesterolemia PI: Jeffrey Geohas, MD
278. A 26 week, randomized, active-controlled safety study of double-blind XXXXX XXXXX in free combination with an inhaled corticosteroid versus an inhaled corticosteroid in adolescent and adult patients with persistent asthma PI: Jeffrey Geohas, MD
279. A randomized, open-label, active-controlled, parallel-group, multicenter, long-term safety trial of treatment with nebulized XXXX in patients with COPD: Golden-5 (XXX for Obstructive Lung Disease via electronic nebulizer) PI: Jeffrey Geohas, MD
280. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase 2A Study with an Open-Label Active Group to Assess the Efficacy and Safety of Once-Daily XXXX in Type 2 Diabetic Patients Inadequately Controlled with Metformin PI: Jeffrey Geohas, MD
281. An Efficacy and Safety Study of Sustained-release XXXXXX in Subjects with Osteoarthritis PI: Jeffrey Geohas, MD
282. Effect of XXXX on 24-hour Blood Glucose in T2DM Patients Inadequately Controlled with Either Metformin or Insulin PI: Jeffrey Geohas, MD
283. A Multi-Center, Double-Blind, Randomized Vehicle-Controlled, Parallel-Group Study to Compare XXXX, 5% with Zovirax (Acyclovir) Cream 5%, and both Active Treatments to a Vehicle Control in Treatment of Recurrent Herpes Simplex Labialis PI: Jeffrey Geohas, MD
284. REASCIEND: Randomized Evaluation of XXXX, to Suppress LDL Cholesterol in Patients With Dyslipidemia PI: Jeffrey Geohas, MD
285. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of XXXX XXXX, 1% (Glenmark Pharmaceuticals Ltd) to XXXX XXXX, (Diclofenac Sodium topical gel) 1% (Novartis Consumer Health, Inc) in Patients with Osteoarthritis (OA) of the Knee PI: Jeffrey Geohas, MD

286. A 12 Week, Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Assess The Efficacy, Safety, Tolerability And Actual Use Of XXXX And An Autoinjector (Pre-Filled Pen) In Subjects With Primary Hyperlipidemia Or Mixed Dyslipidemia
PI: Jeffrey Geohas, MD
287. Dose-finding of XXXX administered subcutaneously once daily versus placebo and XXXX in subjects with type 2 diabetes PI: Jeffrey Geohas, MD
288. A Randomized, Double-Blind, Chronic-Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of XXXX XXXX Relative to Placebo MDI and Open-Label XXXX XXXX in Adult Subjects with Intermittent Asthma or Mild or Moderate Persistent Asthma PI: Jeffrey Geohas, MD
289. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Multi-Center Study to Evaluate the Efficacy and Safety of XXXX Following 12 Weeks Administration in Subjects with Type 2 Diabetes Mellitus on a Stable Dose of Metformin PI: Jeffrey Geohas, MD
290. A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study with a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of XXXXX for the Treatment of Constipation-Predominant Irritable Bowel Syndrome (IBS-C) PI: Jeffrey Geohas, MD
291. A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C) PI: Jeffrey Geohas, MD
292. A Study of Two Doses of XXXX (100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A randomized, double-blind, placebo-controlled parallel group study (SAMURAI) PI: Jeffrey Geohas, MD
293. An Open-label, Long-term, Safety Study of XXXX (100 mg and 200 mg) in the Acute Treatment of Migraine (GLADIATOR)
PI: Jeffrey Geohas, MD
294. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXXX in Combination with Atorvastatin in Patients with Hypercholesterolemia PI: Jeffrey Geohas, MD
295. A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of XXXXX XX 8 mg on the Reduction of LCL-C after 12 Weeks of Administration in Patients with Primary Hyperlipidemia or Mixed Dyslipidemia PI: Jeffrey Geohas, MD
296. A Randomized, Double-Blind, Parallel-Group, Multicenter, Placebo-Controlled, Dose-Ranging Study to Evaluation the Glycemic Effects Safety, and Tolerability of Metformin Delayed-Release in Subjects with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
297. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 4 Study to Assess the Effect of XXXX and XXXX on the Occurance of Major Adverse Cardiovascular Events in Overweight and Obese Subjects with Cardiovascular Disease PI: Jeffrey Geohas, MD
298. A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Phase 3 Study, Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of XXXX Versus Placebo for Preventive Treatment of Chronic Migraine PI: Jeffrey Geohas, MD
299. A Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Phase 3 Study, Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of XXXXXXXX Versus Placebo for Preventive Treatment of Eposodic Migraine
PI: Jeffrey Geohas, MD
300. A Multicenter, Randomized, Double-Blind, Parallel-Group Phase 3 Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of XXXXXXXX for the Preventive Treatment of Migraine PI: Jeffrey Geohas, MD
301. A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of XXXXX versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk with Non-HDL-C Not Adequately Controlled with Maximally Tolerated Statin Therapy PI: Jeffrey Geohas, MD
302. An Open-Label, Long-Term Safety and Tolerability Study of XXXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
PI: Jeffrey Geohas, MD
303. Double-Blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of XXXX on Long-term Cardiovascular Safety and COPD Exacerbations in Patients with Moderate to Very Severe COPD PI: Jeffrey Geohas, MD
304. A Multicenter, Randomized, Double-Blind, Parallel Group Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Administration of XXXX Verses Placebo for the Preventive Treatment of Migraine PI: Jeffrey Geohas, MD
305. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of XXXX Verses Placebo for the Preventive Treatment of Episodic Migraine PI: Jeffrey Geohas, MD
306. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Comparing the Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of XXXX Verses Placebo for the Preventive Treatment of Chronic Migraine PI: Jeffrey Geohas, MD
307. Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation versus XXXXX in Subjects with Type 2 Diabetes Mellitus PI: Jeffrey Geohas, MD
308. A real-world, point-of-care, randomized, parallel group, open, 6-month clinical study to evaluate the effect of a digital disease management tool in patients with type 2 diabetes mellitus PI: Jeffrey Geohas, MD
309. A 12-Week, Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy Safety and Tolerability of XXXX in Subjects with Severe Hypertriglyceridemia (INDIGO-1) PI: Jeffrey Geohas, MD

310. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Add-on Study of XXXXX in Adults with Uncontrolled Type 2 Diabetes on Metformin Therapy PI: Jeffrey Geohas, MD